MET and glioma: Mutations in MET, as well as the dysregulation of other regulators of crosstalk with MET signaling pathways in glioma, have also been previously identified and associated with proliferation, survival, migration, invasion, angiogenesis, stem cell characteristics, therapeutic resistance, and glioblastoma recurrence [52].